Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

BACKGROUND: Anlotinib has been demonstrated its anti-tumor efficacy on non-small cell lung cancer (NSCLC) in clinical trials at 3rd line. However, anlotinib resistance occurs during its administration, and the underlying mechanism is still unclear. METHODS: Anlotinib resistant lung cancer cell line...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jun, Xu, Wei, Qian, Jie, Wang, Shuyuan, Zhang, Bo, Zhang, Lele, Qiao, Rong, Hu, Minjuan, Zhao, Yiming, Zhao, Xiaodong, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416828/
https://www.ncbi.nlm.nih.gov/pubmed/30871526
http://dx.doi.org/10.1186/s12920-019-0482-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416828/
https://www.ncbi.nlm.nih.gov/pubmed/30871526
http://dx.doi.org/10.1186/s12920-019-0482-y

Ejemplares similares